Dr. Macha Kiran Kumar

Dr. Macha Kiran Kumar is a Senior Consultant Medical & Haemato-Oncologist at Yashoda Hospitals, Secunderabad, with over 13 years of dedicated clinical practice in medical oncology. He holds a DM in Medical Oncology from NIMS Hyderabad (2022) and an MD from Osmania Medical College, complemented by European Board Certification in Medical Oncology (ECMO, 2022). His dual expertise spans systemic cancer therapies and blood malignancies, positioning him as a comprehensive oncology resource for complex cases.

Dr. Kiran Kumar specializes in chemotherapy, cancer immunotherapy, targeted molecular therapies, and hormone therapy for breast cancer. He is proficient in managing hematologic malignancies and performing autologous stem cell transplantation. His clinical depth is supported by advanced training in clinical research at Harvard Medical School and certification in pain and palliative care from Pallium India. He was recognized as the topper of his batch in Medical Oncology and received the prestigious Dr. Vijay Anand Reddy Gold Medal. His research has been presented at leading international forums including ESMO Breast Congress (Munich, 2025) and SIOP Congress (USA, 2021).

Dr. Kiran Kumar welcomes international patients from the Gulf region, Africa, and SAARC countries, offering personalized oncological care in a patient-centric environment. He is fluent in English, Hindi, and Telugu, ensuring clear communication and cultural sensitivity. His practice emphasizes holistic support throughout the cancer journey, integrating advanced medical therapies with palliative and pain management expertise.

Yashoda Hospitals, Secunderabad, is a multispecialty institution with strong oncology infrastructure, ICU support, and dedicated international patient services. The hospital's commitment to evidence-based care and international clinical standards makes it an ideal destination for cancer patients seeking specialist care from India. Dr. Kiran Kumar's academic credentials and memberships in the American Society of Clinical Oncology and European Society of Medical Oncology reflect his commitment to maintaining global clinical benchmarks while serving patients locally and internationally.